Basilea Pharmaceutica AG (BSLN.S)
6 Dec 2013
|Market Cap (Mil.):||CHF974.10|
|Shares Outstanding (Mil.):||9.59|
ZURICH, Oct 23 - Basilea Pharmaceutica AG : * Shares open 4.7 percent higher following European approval for superbug
ZURICH, Oct 23 - Swiss biotech group Basilea said it is in talks with potential partners for its superbug antibiotic ceftobiprole, after the treatment won backing from the European regulator to treat hospital and community-acquired pneumonia.
ZURICH, Oct 23 - Basilea Pharmaceutica AG : * Shares indicated 7.8 percent higher after clinching EU approval for
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.